$TERN News

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

Oppenheimer Downgrades Terns Pharmaceuticals to Perform, Removes Price Target $58

Merck: Bullish Setup Into Q1 Earnings

Terns Pharmaceuticals Wins FDA Breakthrough Therapy Designation For TERN-701 In Resistant CML

JP Morgan Maintains Overweight on Terns Pharmaceuticals, Raises Price Target to $44.5

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

Assessing Terns Pharmaceuticals (TERN) Valuation After Strong Recent Share Price Momentum

Truist Securities Downgrades Terns Pharma to Hold, Lowers Price Target to $53

Barclays Downgrades Terns Pharma to Equal-Weight, Lowers Price Target to $53

Here's How Much You Would Have Made Owning Terns Pharma Stock In The Last 5 Years

Citizens Downgrades Terns Pharma to Market Perform

TD Cowen Downgrades Terns Pharma to Hold, Announces $53 Price Target

HC Wainwright & Co. Downgrades Terns Pharma to Neutral, Lowers Price Target to $53

Terns Pharmaceuticals shares are trading higher after the company announced it will be acquired by Merck & Co.

Terns Pharmaceuticals Amends Its Current Exclusive Option And License Agreement With Hansoh Healthtech

Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid Leukemia - Slideshow

Citizens Maintains Market Outperform on Terns Pharma, Raises Price Target to $57

Terns Pharmaceuticals shares are trading higher. The company announced the pricing of its $650 million public offering at $40.00 per share.